ACR Convergence 2023, the world’s premier rheumatology experience, was held Nov. 10–15 at the San Diego Convention Center. Attendees were inspired by lectures from Keynote speaker Avi Goldfarb, PhD, ARP Distinguished Lecturer Kaleb Michaud, PhD, and many, many more. Watch this page for complete coverage. Plus, explore our Psoriatic Arthritis and ANCA-Associated Vasculitis FocusRheums for research reviews, case reports and clinical articles on advances in the diagnosis and management of these conditions. And don’t forget to visit the ACR/ARP Abstracts website.
Focused Content
Psoriatic Arthritis FocusRheum
Explore our coverage of the top research in psoriatic arthritis and additional information presented at ACR Convergence 2023 and much more.
VIEWANCA-Associated Vasculitis FocusRheum
Review our collection of articles on anti-neutrophil cytoplasmic antibody-associated vasculitis, including information on GPA, MPA and EGPA.
VIEW
Previous ACR Meetings
- ACR Convergence 2022
- ACR Convergence 2021
- ACR Convergence 2020
- 2019 ACR/ARP Annual Meeting
- 2018 ACR/ARHP Annual Meeting
- 2017 ACR/ARHP Annual Meeting
- 2016 ACR/ARHP Annual Meeting
- 2015 ACR/ARHP Annual Meeting
- 2014 ACR/ARHP Annual Meeting
- 2010 ACR/ARHP Annual Scientific Meeting
- 2009 ACR/ARHP Annual Scientific Meeting
- 2008 ACR/ARHP Annual Scientific Meeting
- 2006 ACR Annual Meeting
Complete Coverage
Pregnancy Outcomes in Patients Treated with TNF Inhibitors
A study found the continuation of tumor necrosis factor inhibitor (TNFi) treatment in patients with chronic rheumatic inflammatory diseases after pregnancy diagnosis was not associated with worse outcomes than those who discontinued treatment with TNFi’s.
Heterogeneity in Lupus: Lessons from the Autoimmune Centers of Excellence
SAN DIEGO—The Autoimmunity Centers of Excellence (ACE) are a cooperative group funded by the National Institute of Allergy and Infectious Diseases (NIAID) that conduct basic and clinical research on autoimmune diseases.1 ACEs focus on treatment and prevention strategies that induce immune tolerance or modulate the immune system. The goal is to facilitate collaboration across clinicians…
Get AMPed: Understanding RA Through the Accelerating Medicines Partnership
SAN DIEGO—The Accelerating Medicines Partnership (AMP) is a public-private collaboration involving the National Institutes of Health (NIH), the U.S. Food & Drug Administration (FDA), multiple biopharmaceutical and life science companies, and nonprofit organizations, all joined together with the goal of transforming diagnosis and treatments for a multitude of diseases. One such condition that has been…
Brains & Brawn: Exciting Developments in Our Understanding of Myositis
SAN DIEGO—The inflammatory myopathies are a heterogeneous group of conditions that, although discovered decades ago, continue to challenge rheumatologists in terms of their myriad clinical presentations. In Flexing Strong Science on Weak Muscles: Genetics, Genomics and Autoantibodies in Myositis, two speakers provided exceptionally helpful insights into these conditions, using novel tools for analysis. 6 Types…
Old Disease, New Tricks: A Novel Approach to Understanding Gout
SAN DIEGO—Gout has sometimes been called the disease of kings, not only because of the fact that purine-rich foods were long affordable only to wealthier individuals, but also because the disease has been around since the monarchies that existed centuries ago. However, with groundbreaking research leading to a better understanding of gout, we can now…
Rheum in the Court, Law in the Clinic: Health Policy in Global Rheumatology
SAN DIEGO—At ACR Convergence 2023, panelists presented information concerning several policy issues that affect rheumatologists & their patients, including abortion access & the WHO’s Essential Medicine List.
Striving for Equity
SAN DIEGO—At ACR Convergence 2023, panelists provided guidance for reducing disparities and improving health equity for patients who are negatively impacted by social determinants of health.
Can SGLT2 Inhibitors Protect Our SLE Patients?
SAN DIEGO—At ACR Convergence 2023, Plenary Session 2, April M. Jorge, MD, shared data concerning the potential cardio- and renal-protective benefits of sodium-glucose co-transporter-2 inhibitors in patients with systemic lupus erythematosus and lupus nephritis.
Clinical Year in Review: 2023
SAN DIEGO—At ACR Convergence 2023, Philip Seo, MD, MHS, presented an overview of clinical updates in rheumatology from the past year.
No Pain, Much to Gain
SAN DIEGO—Pain is one of the most common symptoms of rheumatic disease, and this session at ACR Convergence 2023 was dedicated to understanding recent research concerning the relationship between pain and inflammation.
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 7
- Next Page »